Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: The Business Research Company | PRODUCT CODE: 1509652

Cover Image

PUBLISHER: The Business Research Company | PRODUCT CODE: 1509652

Hemoglobinopathies Treatment Global Market Report 2024

Published: Pre-Order
PAGES: 175 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
PDF (Single User License)
USD 5000
PDF (Site License)
USD 7500
PDF (Enterprise License)
USD 10000

Add to Cart

Hemoglobinopathies treatment encompasses the management and care offered to individuals affected by genetic disorders involving abnormal or mutated hemoglobin molecules, such as sickle cell disease and thalassemia. The objective of treating hemoglobinopathies is to alleviate symptoms, prevent complications, and potentially offer curative options to enhance patient outcomes and quality of life.

The primary types of treatment for hemoglobinopathies include stem cell therapy and blood transfusion. Stem cell therapy utilizes stem cells to address or prevent a disease or condition, particularly in cases of thalassemia and sickle cell anemia. These treatments can be accessed through various channels, including hospital pharmacies, online providers, drug stores, and retail pharmacies.

The hemoglobinopathies treatment market research report is one of a series of new reports from The Business Research Company that provides hemoglobinopathies treatment market statistics, including hemoglobinopathies treatment industry global market size, regional shares, competitors with a hemoglobinopathies treatment market share, detailed hemoglobinopathies treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobinopathies treatment industry. This hemoglobinopathies treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hemoglobinopathies treatment market size has grown strongly in recent years. It will grow from $8.2 billion in 2023 to $9.01 billion in 2024 at a compound annual growth rate (CAGR) of 9.9%. The growth observed during the historic period can be attributed to several factors, including scientific discoveries, medical advances, patient advocacy, increased public health awareness, and international collaboration through research consortia.

The hemoglobinopathies treatment market size is expected to see rapid growth in the next few years. It will grow to $13.2 billion in 2028 at a compound annual growth rate (CAGR) of 10%. The anticipated growth in the forecast period can be attributed to several factors, including an increasing emphasis on personalized medicine, regulatory support for rare diseases, the implementation of prenatal screening programs, and the availability of genetic counseling services enabling early detection of hemoglobinopathies during pregnancy. Additionally, there is expected to be expanded adoption of disease-modifying therapies. Major trends expected in the forecast period include the development of novel drug therapies, cellular therapies, advancements in precision therapeutics, and the introduction of improved diagnostic tools.

The increasing prevalence of genetic inheritance is expected to drive the growth of the hemoglobinopathies treatment market in the future. Genetic inheritance involves the transmission of characteristics from parents to offspring through DNA during reproduction, whether sexual or asexual. Advances in genetic research and technology have underscored the significance of genetic factors in various diseases, including hemoglobinopathies, leading to improved targeted therapies, personalized medicine, drug development, and diagnosis. For example, according to Gene People, a UK-based registered charity, it is estimated that 1 in every 25 children has a genetic disorder, with approximately 30,000 babies and children newly diagnosed each year. Consequently, the increasing prevalence of genetic inheritance is a driving force behind the expansion of the hemoglobinopathies treatment market.

Key players in the hemoglobinopathies treatment market are actively developing cell-based gene therapies to offer potentially curative treatments for patients with these genetic conditions. Cell-based gene therapies for hemoglobinopathies hold promise in correcting underlying genetic defects, potentially providing long-term or curative effects, alleviating symptoms and complications, and advancing treatment options for affected individuals. For instance, in December 2023, Vertex Pharmaceuticals Incorporated, a US-based biotech company, introduced Casgevy for treating sickle cell disease (SCD) and transfusion-dependent beta thalassemia. Casgevy is a cell-based gene therapy employing CRISPR/Cas9 technology to edit patients' hematopoietic stem cells, enhancing the production of fetal hemoglobin to prevent red blood cell sickling. The therapy involves a one-time treatment process comprising the collection, editing, and reinfusion of the patient's stem cells.

In October 2022, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired Global Blood Therapeutics Inc. for $5.4 billion, aiming to enhance its pipeline and portfolio for rare hematology, particularly in sickle cell disease (SCD), and to leverage its experience to better serve the underserved SCD patient community worldwide. Global Blood Therapeutics Inc., a US-based biopharmaceutical company dedicated to discovering, developing, and delivering drugs for hemoglobinopathies treatment, specializes in sickle cell disease.

Major companies operating in the hemoglobinopathies treatment market are Pfizer Inc., Sanofi S.A., Novartis AG, Bristol Myers Squibb, Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Pharmacosmos A/S, Alnylam Pharmaceuticals, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Gamida Cell Ltd., Beam Therapeutics, Intellia Therapeutics, Adaptimmune Therapeutics, Orchard Therapeutics plc, Fresenius SE & Co. KGaA, Editas Medicine, Agios Pharmaceuticals Inc., Emmaus Life Sciences Inc., Bluebird Bio Inc, CRISPR Therapeutics AG, Bioverativ Inc., Celgene Corporation, EMI Holding Inc.

North America was the largest region in the hemoglobinopathies treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemoglobinopathies treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hemoglobinopathies treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hemoglobinopathies treatment market consists of revenues earned by entities by providing services such as medication, blood transfusions, bone marrow transplantation, gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemoglobinopathies treatment market also includes sales of iron chelation therapy and hydroxyurea. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemoglobinopathies Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemoglobinopathies treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemoglobinopathies treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hemoglobinopathies treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Stem Cell Therapy; Blood Transfusion
  • 2) By Application: Thalassemia; Sick Cell Anemia
  • 3) By Distribution Channel: Hospital Pharmacy; Online Providers; Drug Stores And Retail Pharmacy
  • Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Novartis AG; Bristol Myers Squibb; Gilead Sciences Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.
Product Code: r18149

Table of Contents

1. Executive Summary

2. Hemoglobinopathies Treatment Market Characteristics

3. Hemoglobinopathies Treatment Market Trends And Strategies

4. Hemoglobinopathies Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Hemoglobinopathies Treatment Market Size and Growth

  • 5.1. Global Hemoglobinopathies Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Hemoglobinopathies Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Hemoglobinopathies Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Hemoglobinopathies Treatment Market Segmentation

  • 6.1. Global Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Stem Cell Therapy
  • Blood Transfusion
  • 6.2. Global Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Thalassemia
  • Sick Cell Anemia
  • 6.3. Global Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacy
  • Online Providers
  • Drug Stores And Retail Pharmacy

7. Hemoglobinopathies Treatment Market Regional And Country Analysis

  • 7.1. Global Hemoglobinopathies Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Hemoglobinopathies Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Hemoglobinopathies Treatment Market

  • 8.1. Asia-Pacific Hemoglobinopathies Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Hemoglobinopathies Treatment Market

  • 9.1. China Hemoglobinopathies Treatment Market Overview
  • 9.2. China Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Hemoglobinopathies Treatment Market

  • 10.1. India Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Hemoglobinopathies Treatment Market

  • 11.1. Japan Hemoglobinopathies Treatment Market Overview
  • 11.2. Japan Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Hemoglobinopathies Treatment Market

  • 12.1. Australia Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Hemoglobinopathies Treatment Market

  • 13.1. Indonesia Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Hemoglobinopathies Treatment Market

  • 14.1. South Korea Hemoglobinopathies Treatment Market Overview
  • 14.2. South Korea Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Hemoglobinopathies Treatment Market

  • 15.1. Western Europe Hemoglobinopathies Treatment Market Overview
  • 15.2. Western Europe Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Hemoglobinopathies Treatment Market

  • 16.1. UK Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Hemoglobinopathies Treatment Market

  • 17.1. Germany Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Hemoglobinopathies Treatment Market

  • 18.1. France Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Hemoglobinopathies Treatment Market

  • 19.1. Italy Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Hemoglobinopathies Treatment Market

  • 20.1. Spain Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Hemoglobinopathies Treatment Market

  • 21.1. Eastern Europe Hemoglobinopathies Treatment Market Overview
  • 21.2. Eastern Europe Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Hemoglobinopathies Treatment Market

  • 22.1. Russia Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Hemoglobinopathies Treatment Market

  • 23.1. North America Hemoglobinopathies Treatment Market Overview
  • 23.2. North America Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Hemoglobinopathies Treatment Market

  • 24.1. USA Hemoglobinopathies Treatment Market Overview
  • 24.2. USA Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Hemoglobinopathies Treatment Market

  • 25.1. Canada Hemoglobinopathies Treatment Market Overview
  • 25.2. Canada Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Hemoglobinopathies Treatment Market

  • 26.1. South America Hemoglobinopathies Treatment Market Overview
  • 26.2. South America Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Hemoglobinopathies Treatment Market

  • 27.1. Brazil Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Hemoglobinopathies Treatment Market

  • 28.1. Middle East Hemoglobinopathies Treatment Market Overview
  • 28.2. Middle East Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Hemoglobinopathies Treatment Market

  • 29.1. Africa Hemoglobinopathies Treatment Market Overview
  • 29.2. Africa Hemoglobinopathies Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Hemoglobinopathies Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Hemoglobinopathies Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Hemoglobinopathies Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Hemoglobinopathies Treatment Market Competitive Landscape
  • 30.2. Hemoglobinopathies Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Sanofi S.A.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Novartis AG
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Bristol Myers Squibb
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Gilead Sciences Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Hemoglobinopathies Treatment Market Other Major And Innovative Companies

  • 31.1. Vertex Pharmaceuticals Incorporated
  • 31.2. Pharmacosmos A/S
  • 31.3. Alnylam Pharmaceuticals
  • 31.4. Global Blood Therapeutics Inc.
  • 31.5. Acceleron Pharma Inc.
  • 31.6. Sangamo Therapeutics Inc.
  • 31.7. Gamida Cell Ltd.
  • 31.8. Beam Therapeutics
  • 31.9. Intellia Therapeutics
  • 31.10. Adaptimmune Therapeutics
  • 31.11. Orchard Therapeutics plc
  • 31.12. Fresenius SE & Co. KGaA
  • 31.13. Editas Medicine
  • 31.14. Agios Pharmaceuticals Inc.
  • 31.15. Emmaus Life Sciences Inc.

32. Global Hemoglobinopathies Treatment Market Competitive Benchmarking

33. Global Hemoglobinopathies Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Hemoglobinopathies Treatment Market

35. Hemoglobinopathies Treatment Market Future Outlook and Potential Analysis

  • 35.1 Hemoglobinopathies Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Hemoglobinopathies Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Hemoglobinopathies Treatment Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!